# Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)

> **NCT03921424** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 407 (actual)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** V114
- **BIOLOGICAL:** Prevnar 13™
- **BIOLOGICAL:** PNEUMOVAX™23

## Key facts

- **NCT ID:** NCT03921424
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-05
- **Primary completion:** 2021-05-03
- **Final completion:** 2021-05-03
- **Target enrollment:** 407 (ACTUAL)
- **Last updated:** 2023-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03921424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03921424, "Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03921424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*